Related Experiment Video

Updated: Apr 15, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Irreversible EGFR-TKIs: dreaming perfection

Lorenza Landi1, Federico Cappuzzo1

  • 1Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100 Livorno, Italy.

Translational Lung Cancer Research
|March 26, 2015
PubMed

Insights

Activating mutations in Epidermal Growth Factor Receptor (EGFR) guide Non-Small-Cell Lung Cancer (NSCLC) treatment. While EGFR tyrosine-kinase inhibitors (TKIs) are effective, acquired resistance necessitates new therapies like irreversible panHER inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-Small-Cell Lung Cancer (NSCLC) treatment has evolved, particularly for patients with Epidermal Growth Factor Receptor (EGFR) mutations.
  • First-generation EGFR tyrosine-kinase inhibitors (TKIs) like gefitinib and erlotinib are standard for EGFR-mutated NSCLC but invariably lead to acquired resistance.
  • Key resistance mechanisms include MET amplification and the T790M EGFR gatekeeper mutation.

Purpose of the Study:

  • To review the current landscape of EGFR-mutated NSCLC treatment.
  • To discuss the mechanisms of acquired resistance to first-generation EGFR TKIs.
  • To explore the potential of novel irreversible panHER inhibitors in overcoming acquired resistance.

Main Methods:

  • Literature review of preclinical and clinical studies on EGFR-mutated NSCLC.
  • Analysis of resistance mechanisms to EGFR TKIs.
  • Evaluation of emerging data for irreversible panHER inhibitors.

Main Results:

  • EGFR mutations define a distinct NSCLC subgroup responsive to TKIs.
  • Acquired resistance, driven by MET amplification or T790M mutation, limits long-term efficacy of first-generation TKIs.
  • Preclinical and early clinical data suggest irreversible panHER inhibitors show promise against T790M-mediated resistance.

Conclusions:

  • Irreversible panHER inhibitors represent a promising therapeutic strategy for overcoming acquired resistance in EGFR-mutated NSCLC.
  • Further clinical trials are essential to define the role of afatinib, dacomitinib, and neratinib in NSCLC treatment.
  • Targeting resistance mechanisms is crucial for improving outcomes in NSCLC patients with EGFR mutations.
Keywords:
EGFR (epidermal growth factor receptor)NSCLC (non-small-cell lung cancer)acquired resistanceafatinibdacomitinibneratnib

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
21.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
667
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
574
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K